The weekly litigation news digest is live. Subscribe now

IP Verse

Novel Prime-Boosting Regimens Involving Immunogenic Polypeptides Encoded By Polynucleotides - EP2869841

The patent EP2869841 was granted to Glaxosmithkline on Aug 25, 2021. The application was filed on Jul 5, 2013 under application number EP13734111A. The patent is currently recorded with a legal status of "Revoked".

EP2869841

GLAXOSMITHKLINE
Application Number
EP13734111A
Filing Date
Jul 5, 2013
Status
Revoked
Nov 8, 2024
Publication Date
Aug 25, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
JANSSEN VACCINES & PREVENTIONMay 24, 2022BOULT WADE TENNANTADMISSIBLE

Patent Citations (10) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
EXAMINATIONWO2008085502
EXAMINATIONWO2012021730
INTERNATIONAL-SEARCH-REPORTWO2009025770
INTERNATIONAL-SEARCH-REPORTWO2010073043
INTERNATIONAL-SEARCH-REPORTWO2012085936
OPPOSITIONWO2012021730
OPPOSITIONWO2012089833
OPPOSITIONWO2013139911
OPPOSITIONWO9802179
OTHERWO2012021730

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents